Ferring Pharmaceuticals
ferring.comTotal trials
249
Active
8
Phase 3
93
Total enrollment
1,219,118
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Nadofaragene Firadenovec | — | — | — | 4 | |||
| FE 999326 | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| CLENPIQ | — | — | — | — | — | 1 | |
| MIRALAX | — | — | — | — | — | 1 | |
| REKOVELLE | — | — | — | — | 2 |
Next readouts
- 2027-05-01
- 2027-06
- 2028-06-30
- 2028-06-30
- 2029-11-30
- 2029-11-30
Top conditions
- Prostate Cancer41
- Infertility32
- Nocturia17
- Ulcerative Colitis15
- Cervical Ripening9
- Crohn's Disease8
- Infertility, Female8
- Bowel Preparation5
Frequently asked questions about Ferring Pharmaceuticals
- How many clinical trials does Ferring Pharmaceuticals have on ClinicalTrials.gov?
- Ferring Pharmaceuticals is listed as the lead sponsor on 249 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ferring Pharmaceuticals's trials are in Phase 3?
- 93 of Ferring Pharmaceuticals's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does Ferring Pharmaceuticals focus on?
- Ferring Pharmaceuticals's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Infertility, Nocturia, Ulcerative Colitis, Cervical Ripening.
- When are Ferring Pharmaceuticals's next clinical trial readouts?
- Ferring Pharmaceuticals has 6 upcoming primary-completion readouts tracked here; the soonest is “Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings”, expected around 2027-05-01.